Featured

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide “Vaccinations & Therapeutic Drugs for COVID-19“, containing…

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…

Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…

In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…

Alla luce dei rapidi sviluppi scientifici nel campo della talassemia e dell’anemia falciforme con nuovi farmaci e trattamenti che promettono di rivoluzionare la gestione di queste malattie, la Federazione Internazionale…

In light of the tremendous scientific developments in the field of thalassemia and sickle cell disease (SCD) with new drugs and treatments that promise to revolutionize the management of these…

TIF, its Board of Directors, and International Scientific Advisory Board proudly announce that the 4th edition of the Federation’s most acclaimed and sought-after publication, TIF Guidelines For The Management of…